JP5601836B2 - Ｔｅｓ７およびｔｅｓ７に結合する抗体 - Google Patents

Ｔｅｓ７およびｔｅｓ７に結合する抗体 Download PDF

Info

Publication number
JP5601836B2
JP5601836B2 JP2009536307A JP2009536307A JP5601836B2 JP 5601836 B2 JP5601836 B2 JP 5601836B2 JP 2009536307 A JP2009536307 A JP 2009536307A JP 2009536307 A JP2009536307 A JP 2009536307A JP 5601836 B2 JP5601836 B2 JP 5601836B2
Authority
JP
Japan
Prior art keywords
cancer
tes7
antibody
tumor
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009536307A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010508847A (ja
JP2010508847A5 (https=
Inventor
ジェニー ピー． マザー，
トニー ダブリュー． リアン，
Original Assignee
マクロジェニックス ウエスト， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マクロジェニックス ウエスト， インコーポレイテッド filed Critical マクロジェニックス ウエスト， インコーポレイテッド
Publication of JP2010508847A publication Critical patent/JP2010508847A/ja
Publication of JP2010508847A5 publication Critical patent/JP2010508847A5/ja
Application granted granted Critical
Publication of JP5601836B2 publication Critical patent/JP5601836B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2009536307A 2006-11-08 2007-11-08 Ｔｅｓ７およびｔｅｓ７に結合する抗体 Expired - Fee Related JP5601836B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US85811306P 2006-11-08 2006-11-08
US60/858,113 2006-11-08
US99388207P 2007-09-14 2007-09-14
US60/993,882 2007-09-14
PCT/US2007/023620 WO2008066691A2 (en) 2006-11-08 2007-11-08 Tes7 and antibodies that bind thereto

Publications (3)

Publication Number Publication Date
JP2010508847A JP2010508847A (ja) 2010-03-25
JP2010508847A5 JP2010508847A5 (https=) 2011-11-04
JP5601836B2 true JP5601836B2 (ja) 2014-10-08

Family

ID=39468449

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009536307A Expired - Fee Related JP5601836B2 (ja) 2006-11-08 2007-11-08 Ｔｅｓ７およびｔｅｓ７に結合する抗体

Country Status (7)

Country Link
US (2) US7718774B2 (https=)
EP (1) EP2094307A4 (https=)
JP (1) JP5601836B2 (https=)
AU (1) AU2007325872B2 (https=)
CA (1) CA2668800A1 (https=)
IL (1) IL198592A (https=)
WO (1) WO2008066691A2 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100028256A1 (en) * 2006-11-09 2010-02-04 St Croix Brad Differential gene expression in physiological and pathological angiogenesis
US20100203035A1 (en) * 2007-02-14 2010-08-12 Kwon Eugene D B7-h3 in cancer
ES2589912T3 (es) 2008-04-02 2016-11-17 Macrogenics, Inc. Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
CA2731686C (en) 2008-07-25 2020-04-07 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
PL2350128T3 (pl) 2008-10-22 2015-03-31 Inst Res Biomedicine Sposoby wytwarzania przeciwciał z komórek plazmatycznych
DK2786762T3 (da) 2008-12-19 2019-05-06 Macrogenics Inc Kovalente diabodies og anvendelser deraf
TWI404931B (zh) * 2009-02-20 2013-08-11 財團法人國家同步輻射研究中心 癌化生物樣本之檢測方法及其使用之檢驗試劑
CA2729593A1 (en) * 2009-02-20 2010-08-26 John Wayne Cancer Institute B7-h3 as a biomarker for diagnosing the progression and early lymph node metastasis of cancer
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
EP2542256B1 (en) 2010-03-04 2019-05-22 MacroGenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
WO2012004410A1 (en) * 2010-07-09 2012-01-12 Oslo Universitetssykehus Hf B7-h3 antagonists and taxanes
AU2011286024B2 (en) 2010-08-02 2014-08-07 Macrogenics, Inc. Covalent diabodies and uses thereof
KR102125672B1 (ko) 2011-04-25 2020-06-23 다이이찌 산쿄 가부시키가이샤 항 ｂ７-ｈ３항체
WO2012147713A1 (ja) 2011-04-25 2012-11-01 第一三共株式会社 抗ｂ７－ｈ３抗体
BR112013029892A2 (pt) 2011-05-21 2016-12-20 Macrogenics Inc polipeptídeo, molécula de ligação a antígeno, diacorpo e uso de uma porção polipeptídica de uma proteína de ligação a soro desimunizada
AU2011373387B2 (en) 2011-07-18 2017-06-29 Institute For Research In Biomedicine Neutralizing anti-influenza A virus antibodies and uses thereof
ES2702315T3 (es) 2012-08-24 2019-02-28 Univ California Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
SI3052192T1 (sl) 2013-10-02 2020-11-30 Medimmune, Llc Nevtralizarijoča protitelesa proti-influenci A in njihove uporabe
KR20160135190A (ko) 2014-02-14 2016-11-25 앤드류 에스. 카이 혈관형성 암의 치료를 위한 개선된 방법
MX392761B (es) 2014-07-15 2025-03-21 Medimmune Llc Anticuerpos anti-influenza b neutralizantes y usos de los mismos.
HUE056407T2 (hu) 2015-06-01 2022-02-28 Medimmune Llc Neutralizáló influenzaellenes kötõmolekulák és alkalmazásaik
BR112018006817A2 (pt) 2015-10-08 2018-10-23 Macrogenics Inc método de tratamento do câncer
SG11201805001UA (en) 2016-01-13 2018-07-30 Medimmune Llc Method of treating influenza a
GEP20227398B (en) 2016-04-15 2022-07-25 Macrogenics Inc Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
AU2017279550A1 (en) * 2016-06-08 2019-01-03 Abbvie Inc. Anti-B7-H3 antibodies and antibody drug conjugates
TWI767915B (zh) 2016-06-27 2022-06-21 加州大學董事會 Ror-1與btk拮抗劑的組合
MX2019011117A (es) 2017-03-31 2019-11-05 Jiangsu Hengrui Medicine Co Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
CA3114474A1 (en) 2018-09-30 2020-04-02 Jiangsu Hengrui Medicine Co., Ltd. Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof
CN119080930A (zh) * 2019-07-11 2024-12-06 纪念斯隆凯特琳癌症中心 Dll3靶向抗体及其用途
US20240118284A1 (en) * 2019-10-18 2024-04-11 The Regents Of The University Of California Compositions and methods for detecting plxdc1 and plxcd2 in human tissues
US12590298B2 (en) 2019-10-18 2026-03-31 The Regents Of The University Of California Ex vivo tumor angiogenesis model
KR20220087497A (ko) 2019-10-18 2022-06-24 더 리전츠 오브 더 유니버시티 오브 캘리포니아 병원성 혈관을 표적화하기 위한 화합물 및 방법
AU2020400221A1 (en) * 2019-12-13 2022-05-19 Harbour Biomed (Shanghai) Co., Ltd. Anti-TSLP antibody and uses thereof
EP4257154A4 (en) 2021-02-09 2026-04-22 Medilink Therapeutics Suzhou Co Ltd CONJUGATED WITH A BIOACTIVE SUBSTANCE, ITS PREPARATION PROCESS AND ITS USE

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862925A (en) 1973-07-05 1975-01-28 American Home Prod Preparation of somatotropin release inhibiting factor and intermediates therefor
US3842067A (en) 1973-07-27 1974-10-15 American Home Prod Synthesis of(des-asn5)-srif and intermediates
JPS5726506B2 (https=) 1974-03-08 1982-06-04
US4105603A (en) 1977-03-28 1978-08-08 The Salk Institute For Biological Studies Peptides which effect release of hormones
USRE30548E (en) 1979-08-31 1981-03-17 The Salk Institute For Biological Studies Peptides which effect release of hormones
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5532159A (en) 1994-04-01 1996-07-02 The Ohio State University Monoclonal antibody to canine placental oncofetal protein for detecting cancer
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
AU1672097A (en) 1996-02-15 1997-09-02 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody that recognizes antigens present on the surface of endothelial cell of tumor vessel
WO2000068266A1 (en) 1999-05-11 2000-11-16 Eli Lilly And Company Amyloid precursor protein protease and related nucleic acid compounds
PL354286A1 (en) 1999-08-23 2003-12-29 Dana-Farber Cancer Institutedana-Farber Cancer Institute Pd-1, a receptor for b7-4, and uses therefor
US6429303B1 (en) 1999-09-03 2002-08-06 Curagen Corporation Nucleic acids encoding members of the human B lymphocyte activation antigen B7 family and methods of using the same
US6406840B1 (en) 1999-12-17 2002-06-18 Biomosaic Systems, Inc. Cell arrays and the uses thereof
US20060154313A1 (en) 2000-04-13 2006-07-13 Immunex Corporation Human B7 polypeptide B7-H3A
WO2001089567A1 (en) 2000-05-22 2001-11-29 Idec Pharmaceuticals Corporation Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens
US6965018B2 (en) 2000-06-06 2005-11-15 Bristol-Myers Squibb Company Antibodies directed to B7-related polypeptide, BSL-2
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
US6891030B2 (en) 2000-07-27 2005-05-10 Mayo Foundation For Medical Education And Research T-cell immunoregulatory molecule
WO2002022683A1 (fr) 2000-09-12 2002-03-21 Kirin Beer Kabushiki Kaisha Nouvelle membrane a paroi cellulaire dendritique et son utilisation
US20030134283A1 (en) 2000-10-03 2003-07-17 Peterson David P. Genes regulated in dendritic cell differentiation
US20070015144A9 (en) 2001-05-25 2007-01-18 Genset, S.A. Human cDNAs and proteins and uses thereof
WO2002097046A2 (en) 2001-05-25 2002-12-05 Amgen, Inc. B7 related protein-2 molecules and uses thereof
EP1390497A2 (en) 2001-05-25 2004-02-25 Genset Human cdnas and proteins and uses thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
EP1423402A4 (en) 2001-08-02 2006-07-05 Lilly Co Eli NOVEL ANALOGUES OF POLYPEPTIDES AND HYBRID PROTEINS AND METHODS OF USE
US20040162236A1 (en) 2002-04-01 2004-08-19 John Alsobrook Therapeutic polypeptides, nucleic acids encoding same, and methods of use
ATE488530T1 (de) 2002-06-19 2010-12-15 Raven Biotechnologies Inc Internalisierende antikörper spezifisch für das raag10 zelloberflächenziel
EP2365004B1 (en) 2002-06-21 2016-01-06 Johns Hopkins University School of Medicine Membrane associated tumor endothelium markers
WO2004007527A2 (en) 2002-07-11 2004-01-22 Incyte Corporation Secreted proteins
WO2004023973A2 (en) 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics
CA3007908A1 (en) 2003-03-07 2005-04-14 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
US20050002935A1 (en) 2003-04-17 2005-01-06 Vincent Ling Use of B7-H3 as an immunoregulatory agent
US20050090440A1 (en) 2003-04-28 2005-04-28 Krissansen Geoffrey W. Tumour treating combinations, compositions and methods
US20050070474A1 (en) 2003-04-28 2005-03-31 Krissansen Geoffrey Wayne Methods of treatment and compositions therefor
WO2005017163A2 (en) 2003-08-15 2005-02-24 Imperial College Innovations Limited Phenotypic knockout of cell-surface proteins
DK1773884T3 (da) * 2004-08-03 2012-05-21 Innate Pharma Terapeutiske og diagnostiske fremgangsmåder og sammensætninger til targeting af 4ig-b7-h3 og dets tilsvarende nk-celle-receptor
CA2601472A1 (en) 2005-03-08 2006-09-14 Verenium Corporation Hydrolases, nucleic acids encoding them and methods for improving paper strength
CA2611861C (en) 2005-06-08 2017-11-28 The Brigham And Women's Hospital, Inc. Methods and compositions for the treatment of persistent infections
MX2008007292A (es) 2005-12-08 2008-10-17 Univ Louisville Res Found Composiciones inmunoestimuladoras y metodos.
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function

Also Published As

Publication number Publication date
IL198592A (en) 2015-11-30
JP2010508847A (ja) 2010-03-25
WO2008066691A2 (en) 2008-06-05
US8216570B2 (en) 2012-07-10
EP2094307A2 (en) 2009-09-02
WO2008066691A3 (en) 2008-07-17
US20080226634A1 (en) 2008-09-18
EP2094307A4 (en) 2015-08-26
IL198592A0 (en) 2011-08-01
AU2007325872B2 (en) 2012-12-13
US7718774B2 (en) 2010-05-18
US20100183605A1 (en) 2010-07-22
AU2007325872A1 (en) 2008-06-05
CA2668800A1 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
JP5601836B2 (ja) Ｔｅｓ７およびｔｅｓ７に結合する抗体
US8361475B2 (en) ADAM-9 modulators
US8216578B2 (en) Antibodies to oncostatin M receptor
US8313916B2 (en) KID31 and antibodies that bind thereto
US20060171952A1 (en) JAM-3 and antibodies that bind thereto
US20110045006A1 (en) LUCA2 and Antibodies That Bind Thereto
JP4621674B2 (ja) Ｋｉｄ３およびｋｉｄ３に結合するｋｉｄ３抗体
HK1107402B (en) Kid31 and antibodies that bind thereto
HK1107359B (en) Adam-9 modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110907

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20120126

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130130

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130227

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130401

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20131010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131011

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20131011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140131

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140303

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140310

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140403

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140410

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20140423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140425

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140424

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140804

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140819

R150 Certificate of patent or registration of utility model

Ref document number: 5601836

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD14 Notification of resignation of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7434

Effective date: 20140916

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees